Trial progress and regulatory alignment put TSHA-102 in focus

Taysha Gene Therapies (TSHA) moved into the spotlight after announcing first patient dosing in its REVEAL pivotal trial for TSHA-102, together with written FDA alignment on using ASPIRE safety data for Rett syndrome.

Despite the REVEAL trial update and FDA alignment on TSHA-102, the stock’s 1 month share price return of 14.1% and 7 day share price return of 4.45% show recent weakness, while a very large 1 year total shareholder return and a 3 year total shareholder return above 2x suggest longer term momentum has been strong.

If this kind of biotech news has your attention, it could be a good moment to scan other healthcare stocks that might fit your watchlist next.

With shares giving back some recent gains despite strong multi year returns and clinical momentum, the key question is whether TSHA is still trading at a discount or whether the market is already pricing in future growth.

Most Popular Narrative: 59% Undervalued

Against a last close of $4.51, the most followed narrative on Taysha Gene Therapies points to a fair value of about $11.00, putting a spotlight on what is priced in around REVEAL and TSHA-102.

The analysts have a consensus price target of $6.55 for Taysha Gene Therapies based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $8.0, and the most bearish reporting a price target of just $5.0.

Want to see what is sitting behind that gap between today’s price and the fair value line? The narrative leans on rapid revenue expansion, a shift from heavy losses toward biotech style margins, and a rich future earnings multiple that is usually reserved for companies with strong confidence around their pipelines. Curious which assumptions need to hold for TSHA-102 and REVEAL to support that kind of pricing power?

Result: Fair Value of $11.00 (UNDERVALUED)

However, this depends on REVEAL continuing to meet FDA expectations and on Taysha managing ongoing losses of about US$99.9 million without stretching its trial funding.

Build Your Own Taysha Gene Therapies Narrative

If you see the story differently or prefer to weigh the data points yourself, you can build and publish your own view in just a few minutes, starting with Do it your way.

A great starting point for your Taysha Gene Therapies research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If you stop with just one stock, you might miss opportunities that fit your style even better, so use the screener to surface ideas that truly match your goals.

• Spot potential value by scanning these 880 undervalued stocks based on cash flows that currently trade below what their cash flows might suggest.
• Catch early growth themes by filtering for these 24 AI penny stocks tied to artificial intelligence trends you want exposure to.
• Target regular income by focusing on these 12 dividend stocks with yields > 3% that already offer yields above 3%.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.